Haemonetics (NYSE:HAE) Stock: Insider Farris Maryanne Maunsell Sells 836 Shares

Haemonetics Corporation (NYSE:HAE) CAO Farris Maryanne Maunsell sold 836 shares of the stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $120.99, for a total transaction of $101,147.64. Following the sale, the chief accounting officer owned 5,828 shares in the company, valued at $705,129.72. This represents a 12.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Haemonetics Price Performance

NYSE:HAE traded up $0.45 during mid-day trading on Friday, reaching $123.16. The stock had a trading volume of 439,677 shares, compared to its average volume of 808,065. Haemonetics Corporation has a 12 month low of $51.00 and a 12 month high of $132.00. The stock has a market capitalization of $5.61 billion, a PE ratio of 55.23, a P/E/G ratio of 2.41 and a beta of 0.63. The company has a debt-to-equity ratio of 1.24, a current ratio of 2.84 and a quick ratio of 1.83. The stock has a 50-day simple moving average of $112.93 and a two-hundred day simple moving average of $81.08.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.06. The firm had revenue of $357.76 million during the quarter, compared to analysts’ expectations of $345.15 million. Haemonetics had a return on equity of 27.42% and a net margin of 7.52%. The company’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the company earned $1.27 earnings per share. On average, equities analysts anticipate that Haemonetics Corporation will post 5.32 earnings per share for the current year.

Hedge Funds Weigh In On Haemonetics

Several large investors have recently bought and sold shares of the company. First Trust Advisors LP boosted its stake in shares of Haemonetics by 8.3% during the third quarter. First Trust Advisors LP now owns 68,637 shares of the medical instruments supplier’s stock valued at $7,227,000 after purchasing an additional 5,279 shares in the last quarter. Advisors Asset Management Inc. acquired a new position in shares of Haemonetics in the third quarter valued at approximately $194,000. Private Wealth Asset Management LLC bought a new position in Haemonetics in the 3rd quarter valued at approximately $217,000. Focus Advisor Solutions LLC bought a new position in Haemonetics in the 3rd quarter valued at approximately $345,000. Finally, Genesis Wealth Advisors LLC bought a new position in Haemonetics in the 3rd quarter valued at approximately $243,000. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on HAE shares. Mizuho set a $165.00 target price on Haemonetics in a research note on Thursday, November 5th. JPMorgan Chase & Co. raised their price target on shares of Haemonetics from $62.00 to $86.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Robert W. Baird lifted their price target on shares of Haemonetics from $96.00 to $119.00 and gave the company an “outperform” rating in a report on Friday, August 21st. Barrington Research upped their price objective on shares of Haemonetics from $140.00 to $145.00 and gave the stock an “outperform” rating in a research report on Friday, November 6th. Finally, Wall Street Zen downgraded shares of Haemonetics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 7th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.00.

Haemonetics Company Profile

Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals. The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.